Research graph
References from Individualized Ofatumumab versus Fixed Low‐Dose Rituximab in MuSK‐Antibody‐Positive Myasthenia Gravis: A Multicenter Retrospective Cohort Study. Local targets link to admitted publications; unresolved targets remain external evidence.
MuSK antibodies, lessons learned from poly- and monoclonality
10.1016/j.jaut.2020.102488 · 2020 · External reference
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
10.3389/fimmu.2023.1212757 · 2023 · External reference
Rituximab treatment of myasthenia gravis: a systematic review
10.1002/mus.25597 · 2017 · External reference
Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis
10.3389/fneur.2024.1439899 · 2024 · External reference
Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis
10.1038/s41598-025-90937-w · 2025 · External reference
Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review
10.1212/wnl.0000000000004341 · 2017 · External reference
Opportunities and limitations of B cell depletion approaches in SLE
10.1038/s41584-024-01210-9 · 2025 · External reference
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
10.1177/13524585221079731 · 2022 · External reference
Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells
10.3389/fneur.2023.1278250 · 2023 · External reference
Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab
2024 · External reference
Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study
2026 · External reference
Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)
2025 · External reference
Utilization of MG-ADL in myasthenia gravis clinical research and care
10.1002/mus.27476 · 2022 · External reference
Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial
10.1002/mus.23988 · 2014 · External reference
Performance of individual items of the quantitative myasthenia gravis score
10.1016/j.nmd.2013.02.008 · 2013 · External reference
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis
10.1016/j.msard.2021.102787 · 2021 · External reference
Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability
10.1007/s40265-024-02011-w · 2024 · External reference
Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
10.1093/rheumatology/ker417 · 2012 · External reference
Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody
10.1002/mus.27233 · 2021 · External reference
The burden of recurrent respiratory tract infections in adult population: a population-based study in primary care
10.1093/fampra/cmae009 · 2024 · External reference
Efficacy and safety of low-dose rituximab in MuSK antibody-positive myasthenia gravis: a single-center retrospective study
2026 · External reference
The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis
10.1002/acn3.564 · 2018 · External reference
Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis
10.1001/jamaneurol.2016.4190 · 2017 · External reference
Efficacy and safety of low-dose rituximab in Anti-MuSK myasthenia gravis patients: a retrospective study
10.2147/ndt.s358851 · 2022 · External reference
Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study
10.1007/s00415-019-09296-y · 2019 · External reference
Rituximab in refractory myasthenia gravis: extended prospective study results
10.1002/mus.26156 · 2018 · External reference
Long-lasting treatment effect of rituximab in MuSK myasthenia
10.1212/wnl.0b013e3182407982 · 2012 · External reference
Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis
10.1177/1756286419871187 · 2019 · External reference
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
10.4161/mabs.22771 · 2013 · External reference
Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies
10.1016/j.ekir.2024.12.012 · 2025 · External reference
Human or chimeric monoclonal Anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial
10.1681/asn.2021040561 · 2021 · External reference
Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex
10.1016/j.coi.2005.03.001 · 2005 · External reference
Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes
10.3390/ijms18061249 · 2017 · External reference
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >/=65 years old
10.1002/mus.27393 · 2021 · External reference
High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria
10.1007/s00415-019-09191-6 · 2019 · External reference
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
10.1080/08830185.2017.1346092 · 2017 · External reference
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
10.1016/j.anai.2023.01.018 · 2023 · External reference
Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study
10.1007/s00296-021-04847-x · 2021 · External reference
